

Cat No. 64-Q25

AT9283


2mg



For research purposes only

AT9283 is a multi-targeted kinase inhibitor of both Aurora kinases (A & B) as well as Janus kinase (Jak) 2. It also targets serine/threonine protein kinases associated with myeloid cell proliferation. AT9283 inhibited growth and survival of multiple solid tumor cell lines.

TECHNICAL INFORMATION



Other Names: 1-cyclopropyl-3-(3-(5-(morpholinomethyl)-1H-benzo[d]imidazol-2-yl)-1H-pyrazol-4-yl)urea

Chemical Formula: C₁₉H₂₃N₇O₂

CAS Number: 896466-04-9

PubChem Substance ID: 11696609

Molecular Weight: 381.43

Purity: >98%

Appearance: Powder

Solubility: DMSO

IC₅₀ : Aurora A: 3nM, Aurora B: 3nM, JAK2: 1.2nM

STORAGE AND HANDLING

Storage: Store at 4°C and protected from light. Following reconstitution, store aliquots at -20°C.

Stability: Stock solutions stable at -20°C for up to 2 years.

Shipping Conditions: Shipped at room temperature.

PRODUCT USE

Soluble in ≥76mg/mL of DMSO.

REFERENCES

1. Qi, W., et al (2012). AT9283, a novel aurora kinase inhibitor, suppresses tumor growth in aggressive B-cell lymphomas. *Int. J. Cancer*. 130:2997-3005.
2. Santo, L., et al (2011). Antimyeloma activity of a multi-targeted kinase inhibitor, AT9283, via potent aurora kinase and Stat3 inhibition either alone or in combination with lenalidomide. *Cin. Cancer Res*. 17:3259-71.
3. Tanaka, R., et al (2010). Activity of the multitargeted kinase inhibitor, AT9283, in imatinib-resistant BCR-ABL-positive leukemic cell. *Blood*. 116:2089-95.